Atomoxetine and Fluoxetine Activate AMPK-ACC-CPT1 Pathway in Human SH-SY5Y and U-87 MG Cells
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective Atomoxetine and fluoxetine are psychopharmacologic agents associated with loss of appetite and weight. Adenosine monophosphate-activated protein kinase (AMPK) is the cellular energy sensor that regulate metabolism and energy, being activated by fasting and inhibited by feeding in the hypothalamus.Methods Human brain cell lines (SH-SY5Y and U-87 MG cells) were used to study the outcome of atomoxetine and fluoxetine treatment in the activity of AMPK-acetyl-CoA carboxylase (ACC)- carnitine palmitoyl transferase 1 (CPT1) pathway and upstream regulation by calcium/calmodulin-dependent kinase kinase β (CaMKKβ) using immunoblotting and CPT1 enzymatic activity measures.Results Phosphorylation of AMPK and ACC increased significantly after atomoxetine and fluoxetine treatment in the first 30–60 minutes of treatment in the two cell lines. Activation of AMPK and inhibition of ACC was associated with an increase by 5-fold of mitochondrial CPT1 activity. Although the neuronal isoform CPT1C could be detected by immunoblotting, activity was not changed by the drug treatments. In addition, the increase in phospho-AMPK and phospho-ACC expression induced by atomoxetine was abolished by treatment with STO-609, a CaMKKβ inhibitor, indicating that AMPK-ACC-CPT1 pathway is activated through CaMKKβ phosphorylation.Conclusion These findings indicate that at the cellular level atomoxetine and fluoxetine treatments may activate AMPK-ACC-CPT1 pathways through CaMKKβ in human SH-SY5Y and U-87 MG cells.
Abstract
Objective Atomoxetine and fluoxetine are psychopharmacologic agents associated with loss of appetite and weight. Adenosine monophosphate-activated protein kinase (AMPK) is the cellular energy sensor that regulate metabolism and energy, being activated by fasting and inhibited by feeding in the hypothalamus.Methods Human brain cell lines (SH-SY5Y and U-87 MG cells) were used to study the outcome of atomoxetine and fluoxetine treatment in the activity of AMPK-acetyl-CoA carboxylase (ACC)- carnitine palmitoyl transferase 1 (CPT1) pathway and upstream regulation by calcium/calmodulin-dependent kinase kinase β (CaMKKβ) using immunoblotting and CPT1 enzymatic activity measures.Results Phosphorylation of AMPK and ACC increased significantly after atomoxetine and fluoxetine treatment in the first 30–60 minutes of treatment in the two cell lines. Activation of AMPK and inhibition of ACC was associated with an increase by 5-fold of mitochondrial CPT1 activity. Although the neuronal isoform CPT1C could be detected by immunoblotting, activity was not changed by the drug treatments. In addition, the increase in phospho-AMPK and phospho-ACC expression induced by atomoxetine was abolished by treatment with STO-609, a CaMKKβ inhibitor, indicating that AMPK-ACC-CPT1 pathway is activated through CaMKKβ phosphorylation.Conclusion These findings indicate that at the cellular level atomoxetine and fluoxetine treatments may activate AMPK-ACC-CPT1 pathways through CaMKKβ in human SH-SY5Y and U-87 MG cells.
참고문헌 (45)
- Kishi T, "Body weight is regulated by the brain : a link between feeding and emotion", Mol Psychiatry, 10, pp.132~146 (2005)
- Sestan-Pesa M, "Metabolism and mental illness", Trends Mol Med, 22, pp.174~183 (2016)
- Himmerich H, "Weight gain and metabolic changes during treatment with antipsychotics and antidepressants", Endocr Metab Immune Disord Drug Targets, 15, pp.252~260 (2015)
- Kim Y, "Mitochondria, metabolism, and redox mechanisms in psychiatric disorders", Antioxid Redox Signal, 31, pp.275~317 (2019)
- Engl E, "Non-signalling energy use in the brain", J Physiol, 593, pp.3417~3429 (2015)
- Lennie P, "The cost of cortical computation", Curr Biol, 13, pp.493~497 (2003)
- Hardie DG, "The AMP-activated", SNF1 protein kinase subfamily : metabolic sensors of the eukaryotic cell?, 1998, pp.67, 821~855
- Hardie DG, "AMPK : a nutrient and energy sensor that maintains energy homeostasis", Nat Rev Mol Cell Biol, 13, pp.251~262 (2012)
- Woods A, "LKB1 is the upstream kinase in the AMP-activated protein kinase cascade", Curr Biol, 13, pp.2004~2008 (2003)
- Hurley RL, "The Ca2+", calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases, 2005, pp.280, 29060~29066
- Woods A, "Ca2+", calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells, 2005, pp.2, 21~33
- Hardie DG, "The AMP-activated protein kinase--fuel gauge of the mammalian cell?", Eur J Biochem, 246, pp.259~273 (1997)
- Ha J, "Critical phosphorylation sites for acetyl-CoA carboxylase activity", J Biol Chem, 269, pp.22162~22168 (1994)
- McGarry JD, "The role of malonyl-coa in the coordination of fatty acid synthesis and oxidation in isolated rat hepatocytes", J Biol Chem, 253, pp.8294~8300 (1978)
- Ruderman NB, "Minireview : malonyl CoA, AMPactivated protein kinase, and adiposity", Endocrinology, 144, pp.5166~5171 (2003)
- Hummer M, "Weight gain induced by clozapine", Eur Neuropsychopharmacol, 5, pp.437~440 (1995)
- Kim MK, "The effect of clozapine on the AMPK-ACC-CPT1 pathway in the rat frontal cortex", Int J Neuropsychopharmacol, 15, pp.907~917 (2012)
- Kowalchuk C, "Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons", Psychoneuroendocrinology, 104, pp.42~48 (2019)
- Bymaster FP, "Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat : a potential mechanism for efficacy in attention deficit", hyperactivity disorder, 2002, pp.27, 699~711
- nisoxetine binding in rat brain, "J Neurochem", 1995, 2792~2800
- Osland ST, "Pharmacological treatment for attention deficit hyperactivity disorder(ADHD)in children with comorbid tic disorders", Cochrane Database Syst Rev, 6, pp.CD007990~ (2018)
- Wong DT, "Prozac(fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug : twenty years since its first publication", Life Sci, 57, pp.411~441 (1995)
- Craig PM, "Profiling hepatic microRNAs in zebrafish : fluoxetine exposure mimics a fasting response that targets AMPactivated protein kinase(AMPK)", PLoS One, 9, pp.e95351~ (2014)
- Halford JC, "Serotonergic drugs : effects on appetite expression and use for the treatment of obesity", Drugs, 67, pp.27~55 (2007)
- Lam DD, "Serotonin and energy balance : molecular mechanisms and implications for type 2 diabetes", Expert Rev Mol Med, 9, pp.1~24 (2007)
- Tokumitsu H, "STO-609, a specific inhibitor of the Ca(2+)", calmodulin-dependent protein kinase kinase, 2002, pp.277, 15813~15818
- Stein SC, "The regulation of AMP-activated protein kinase by phosphorylation", Biochem J, 345, pp.437~443 (2000)
- Sierra AY, "CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity", J Biol Chem, 283, pp.6878~6885 (2008)
- McGarry JD, "The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis", Eur J Biochem, 244, pp.1~14 (1997)
- Chen JQ, "Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells", Biochim Biophys Acta, 1826, pp.370~384 (2012)
- Kola B, "Role of AMP-activated protein kinase in the control of appetite", J Neuroendocrinol, 20, pp.942~951 (2008)
- Andersson U, "AMP-activated protein kinase plays a role in the control of food intake", J Biol Chem, 279, pp.12005~12008 (2004)
- Minokoshi Y, "Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase", Nature, 415, pp.339~343 (2002)
- Hu Z, "Hypothalamic malonyl-CoA as a mediator of feeding behavior", Proc Natl Acad Sci U S A, 100, pp.12624~12629 (2003)
- He W, "Molecular disruption of hypothalamic nutrient sensing induces obesity", Nat Neurosci, 9, pp.227~233 (2006)
- Obici S, "Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production", Nat Med, 9, pp.756~761 (2003)
- Hahn M, "Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo : an animal model", Schizophr Res, 131, pp.90~95 (2011)
- Doghramji K, "Adverse effects of psychotropic medications on sleep", Sleep Med Clin, 11, pp.503~514 (2016)
- Morais M, "The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression", Transl Psychiatry, 7, pp.e1146~ (2017)
- Rief W, "Rethinking psychopharmacotherapy : the role of treatment context and brain plasticity in antidepressant and antipsychotic interventions", Neurosci Biobehav Rev, 60, pp.51~64 (2016)
- Hawley SA, "Complexes between the LKB1 tumor suppressor, STRAD alpha", beta and MO25 alpha, J Biol, pp.2003, 2[DOI]
- Hawley SA, "5’-AMP activates the AMP-activated protein kinase cascade, and Ca2+", calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms, 1995, pp.270, 27186~27191
- Racioppi L, "Calcium", calmodulin-dependent protein kinase kinase 2 : roles in signaling and pathophysiology, 2012, pp.287, 31658~31665
- Towler MC, "AMP-activated protein kinase in metabolic control and insulin signaling", Circ Res, 100, pp.328~341 (2007)
- Sun P, "Inhibition of calcium", calmodulin-dependent protein kinase kinase(CaMKK)exacerbates impairment of endothelial cell and blood-brain barrier after stroke, 2019, pp.49, 27~39